A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of GrafixCORE for the Treatment of Complex Diabetic Foot Wounds With Exposed Tendon and or Bone

Trial Profile

A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of GrafixCORE for the Treatment of Complex Diabetic Foot Wounds With Exposed Tendon and or Bone

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Placental-derived mesenchymal stem cell therapy Osiris Therapeutics (Primary)
  • Indications Diabetic foot; Wounds
  • Focus Therapeutic Use
  • Sponsors Osiris Therapeutics
  • Most Recent Events

    • 06 Oct 2016 According to a Osiris Therapeutics media release, the company will present data from this study at the Symposium on Advanced Wound Care (SAWC) Fall Conference.
    • 04 Mar 2016 Results published in Grafix media release.
    • 01 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top